Advaxis has a broad pipeline maximizing the potential of Lm Technology™ in three separate areas of focus:
CLINICAL STAGE ASSETS
Four investigational immunotherapies targeting a range of types of cancers.
Advaxis’ lead Lm Technology™ immunotherapy axalimogene filolisbac (AXAL) targets HPV-associated cancers and is in a Phase 3 clinical trial for high-risk, locally advanced cervical cancer.
ADXS-PSA is under investigation for targeting the prostate-specific antigen (PSA) associated with prostate cancer and is in clinical development both as a monotherapy and in combination with immune checkpoint inhibitors for the treatments of metastatic castration-resistant prostate cancer (mCRPC).
From personalized to off-the-shelf our neoantigen-directed constructs are in leveraging advances in gene sequencing to pursue individualized approaches to cancer therapies.
Advaxis has embraced strategic collaborations with other major biopharmaceutical companies for the development and commercialization of some of its proprietary cancer immunotherapies. In addition, Advaxis is developing numerous distinct proprietary immunotherapies directly or in partnership with recognized cancer centers of excellence and with support from advocacy foundations.